nodular lymphocyte-predominant Hodgkin’s lymphoma

Rare Disease — Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma: Literature Review and Own Data

LYMPHOID TUMORS , , , ,

E.A. Demina1, G.S. Tumyan1, A.A. Chekan1, M.Yu. Kichigina1, A.S. Antipova1, N.A. Probatova1, A.I. Pavlovskaya1, N.V. Kokosadze1, A.M. Kovrigina2, O.P. Trofimova1, E.A. Osmanov1

1 N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

2 Hematology Research Center under the Ministry of Health of the Russian Federation, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: E.A. Demina, DSci, Professor, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel: +7(499)324-90-89; e-mail: drdemina@yandex.ru

For citation: Demina E.A., Tumyan G.S., Chekan A.A., Kichigina M.Yu., Antipova A.S., Probatova N.A., Pavlovskaya A.I., Kokosadze N.V., Kovrigina A.M., Trofimova O.P., Osmanov E.A. Rare Disease — Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma: Literature Review and Own Data. Klin. Onkogematol. 2014; 7(4): 522–532 (In Russ.).

ABSTRACT

Nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL) is a rare disorder; it constitutes only 5 % of all cases of Hodgkin’s lymphoma (the morbidity rate is 1.5 per one million). The disease differs from classical Hodgkin’s lymphoma (cHL) in both immunohistochemical (marked CD20 expression in LP cells) and clinical features (prevalence of the early stage disease, indolent course with delayed relapses and trends toward transformation into diffuse large B cell lymphoma). Since the number of patients in prospective NLPHL-focused trials is limited, treatment algorithms have been based on retrospective data; these are usually obtained from cHL and indolent B cell lymphoma treatment strategies. Patients rarely die from NLPHL; in fact, secondary malignancies and other treatment related toxicities generally contribute to overall mortality. Over the past decade, there has been a series of NLPHL-related publications describing prescription of rituximab for newly diagnosed diseases and for relapses, including patients at high risk of diseases transformation. Besides, the role of the “wait and watch”, radiation treatment, and chemotherapy has been discussed. Our own experience in the use of rituximab in NLPLH patients demonstrated its efficacy at different stages and at different phases of the disease.

Keywords: nodular lymphocyte-predominant Hodgkin’s lymphoma, diagnosis, clinical characteristics, treatment, rituximab.

Accepted: September 8, 2014

Read in PDF (RUS)pdficon

REFERENCES

  1. Jackson H., Parker F. Hodgkin’s disease II. Pathology. N. Engl. J. Med. 1944; 231: 35–44.
  2. Lukes R., Butler J., Hicks E. Natural history of Hodgkin’s disease as related to its pathological picture. Cancer. 1966; 19: 317–44.
  3. Harris N.L., Jaffe E.S., Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361–92.
  4. Jaffe E.S., Harris N.L., Stein H. et al. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2001: 240–3.
  5. Swerdlow S.H., Campo E., Harris N.L. et al. (eds.) WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.
  6. Diehl V., Sextro M., Franclin J. et al. Clinical presentation, course, and prognostic factors in lymphocyte predominant Hodgkin’s disease: report from European Task Force on Lymphoma (ETFL) Project on lymphocyte-predominant Hodgkin’s disease. J. Clin. Oncol. 1999; 17: 776–83.
  7. Saarinen S., Pukkala E., Vahteristo P. et al. High Familial Risk in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. JCO. 2013; 31(7): 938–43.
  8. Mason D.Y., Banks P.M., Chan J. et al. Nodular lymphocyte-predominant Hodgkin’s disease. A distinct clinicopathological entity. Am. J. Surg. Pathol. 1994; 18: 526–30.
  9. Engert A., Horning S.J. (eds.) Hodgkin Lymphoma: A Comprehensive Update on Diagnostics and Clinics (Hematologic Malignancies). Springer, 2011.
  10. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупнокле- точные лимфомы. Медицинское информационное агентство, 2007. [Kovrigina A.M., Probatova N.A. Limfoma Khodzhkina i krupnokletochnye limfomy. (Hodgkin’s lymphoma and larg cell lymphomas.) Meditsinskoe informatsionnoe agentstvo Publ.; 2007.]
  11. Nogova L., Reineke T., Brillant C. et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J. Clin. Oncol. 2008; 26: 434–9.
  12. Лимфома Ходжкина. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. Современная онкология. Экстравыпуск. 2013: 11–5. [Poddubnaya I.V., Savchenko V.G., eds. Limfoma Khodzhkina. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. (Hodgkin’s lymphoma. Russian clinical guidelines in diagnosis and treatment of lymphoproliferative disorders.) Sovremennaya onkologiya. Additional release; 2013. pр. 11–5.]
  13. Fanale M. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? Hematology (EHA 2013 Education book). 2013: 406–16.
  14. Kuppers R., Rajewsky K., Zhao M. et al. Hodgkin disease: Hodgkin and Reed–Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B-cells at various stages of development. Proc. Natl. Acad. Sci. USA. 1994; 91: 10962–6.
  15. Marafioti T., Hummel M., Anagnostopoulos I. et al. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal center B-cells. N. Engl. J. Med. 1997; 337(7): 453–8.
  16. Isaacson P.G. Malignant lymphomas with a follicular growth pattern. Histopathology. 1996; 28(6): 487–95.
  17. Brune V., Tiacci E., Pfeil I. et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J. Exp. Med. 2008; 205(10): 2251–68.
  18. Mottok A., Renne C., Willenbrock K. et al. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAC2 expression and activation of STAT6. Blood. 2007; 110(9): 3387–90.
  19. Schumacher A.M., Schmitz R., Brune V. et al. Mutations in the genes coding for den NJ-kB regulation factors IkBa and A20 are uncommon in nodular lymphocyte-predominant Hodgkin lymphoma. Haematologica. 2010; 95: 153–7.
  20. Liso A., Capello D., Marafiotti T. et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood. 2006; 108(3): 1013–20.
  21. Rahemtullah A., Reichard K.K., Preffer F.I. et al. A double-positive CD4+CD8+ T-cells population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma. Am. J. Clin. Pathol. 2006; 125(5): 153–7.
  22. Henry-Amar M. Second cancer after treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s disease. Ann. Oncol. 1992; 3(Suppl. 4): 117.
  23. Saad J., Sirop S.J., Habermann T.M. et al. Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. Blood (ASH Annual Meeting Abstracts). 2012; 120: 1525.
  24. Al-Mansour M., Connors J.M., Gascoyne R.D. et al. Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma. J. Clin. Oncol. 2010; 28: 793–9.
  25. Bennett M.H., MacLennan K.A., Vaughan Hudson G. et al. Non-Hodgkin’s lymphoma arising in patients treated for Hodgkin’s disease in the BNLI: A 20- year experience—British National Lymphoma Investigation. Ann. Oncol. 1991; 2(Suppl. 2): 83–92.
  26. Orlandi E., Lazzarino M., Brusamolino E. et al. Nodular lymphocyte predominance Hodgkin’s disease: Long-term observation reveals a continuous pattern of recurrence. Leuk. Lymphoma. 1997; 26: 359–68.
  27. Wickert R.S., Weisenburger D.D., Tierens A. et al. Clonal relationship between lymphocytic predominance Hodgkin’s disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood. 1995; 86: 2312–20.
  28. Hell K., Hansmann M.L., Pringle J.H. et al. Combination of Hodgkin’s disease and diffuse large cell lymphoma: An in situ hybridization study for immunoglobulin light chain messenger RNA. Histopathology. 1995; 27: 491–9.
  29. Greiner T.C., Gascoyne R.D., Anderson M.E. et al. Nodular lymphocytepredominant Hodgkin’s disease associated with large-cell lymphoma: Analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood. 1996; 88: 657–66.
  30. Sirop S.J., Habermann T.M., Macon W.R. et al. Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. Blood (ASH Annual Meeting Abstracts). 2012; 120(21): Abstract 1525.
  31. Farrell K., Mckay P., Leach M. Nodular Lymphocyte Predominant Hodgkin Lymphoma behaves as a Distinct Clinical Entity with Good Outcome: Evidence from 14 year Follow-up from the West of Scotland Cancer Network. Ann. Oncol. 2011; 22(Suppl. 4): Abstract 291.
  32. Pappa V.I., Norton A.J., Gupta R.K. et al. Nodular type of lymphocyte predominant Hodgkin’s disease. A clinical study of 50 cases. Ann. Oncol. 1995; 6(6): 559–65.
  33. Connors J.M. Lymphocyte predominant Hodgkin’s lymphoma. ASH (Education Program Book). 2001: 1: 187–90.
  34. Borg-Grech A., Radford J.A., Crowther D., Swindell R., Harris M. A comparative study of the nodular and diffuse variants of lymphocytepredominant Hodgkin’s disease. J. Clin. Oncol. 1989; 7(9): 1303–9.
  35. Regula D.P. Jr., Hoppe R.T., Weiss L.M. Nodular and diffuse types of lymphocyte predominance Hodgkin’s disease. N. Engl. J. Med. 1988; 318(4): 214–9.
  36. Crennan E., D’Costa I., Liew K.H. et al. Lymphocyte predominant Hodgkin’s disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int. J. Radiat. Oncol. Biol. Phys. 1995; 31(2): 333–7.
  37. Hansmann M.L., Zwingers T., Boske A., Loffler H., Lennert K. Clinical features of nodular paragranuloma (Hodgkin’s disease, lymphocyte predominance type, nodular). J. Cancer Res. Clin. Oncol. 1984; 108(3): 321–30.
  38. Bodis S., Kraus M.D., Pinkus G. et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin’s disease. J. Clin. Oncol. 1997; 15(9): 3060–6.
  39. Pellegrino B., Terrier-Lacombe M.J., Oberlin O. et al. Lymphocytepredominant Hodgkin’s lymphoma in children: therapeutic abstention after initial lymph node resection — a study of the French Society of Pediatric Oncology. J. Clin. Oncol. 2003; 21: 2948–52.
  40. Murphy S.B., Morgan E.R., Katzenstein H.M. et al. Results of little for not treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J. Pediatr. Hematol. Oncol. 2003; 25: 684–7.
  41. Mauz-Koerholz С., Hasenclever D., Gorde-Grosjean S. et al. Surgical resection alone in children with limited stage lymphocyte predominant Hodgkin’s lymphoma — the experience of the EuroNet-PHL group [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108(11): 2470.
  42. Appel B., Ehrich P., Chen L. et al. Treatment of pediatric stage IA lymphocyte-predominant Hodgkin’s lymphoma with surgical resection alone: A report from the Children’s Oncology Group. J. Clin. Oncol. 2012; 30: 9524.
  43. Biasoli I., Stamatoullas A., Meignin V. et al. Nodular, LymphocytePredominant Hodgkin’s Lymphoma. Cancer. 2010; 116: 631–9.
  44. Schlembach P., Wilder R., Jones D. et al. Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J. 2002; 8(5): 377–83.
  45. Wirth A., Yuen K., Barton M. et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australian Radiation Oncology Lymphoma Group. Cancer. 2005; 104(6): 1221–9.
  46. Chen R.C., Chin M.S., Ng A.K. et al. Early stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J. Clin. Oncol. 2010; 28(1): 136–41.
  47. Nogova L., Reineke T., Eich H.T. et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patient with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann. Oncol. 2005; 16(10): 1683–7.
  48. Eichenauer D.A., Fuchs M., Pluetschow A. et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011; 118(16): 4363–5.
  49. Canellos G.P., Mauch P. What Is the Appropriate Systemic Chemotherapy for Lymphocyte-Predominant Hodgkin’s Lymphoma? J. Clin. Oncol. 2010; 28(1): е8.
  50. Fanale M.A., Lai C.M., McLaughlin P. et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin’s Lymphoma (NLPHL) Patients Treated with R-CHOP. Blood (ASH Annual Meeting Abstracts). 2010; 116(21): Abstract 2812.
  51. Advani R.H., Hope R.T. How I treat lymphocyte predominant Hodgkin Lymphoma. Blood. 2013; 122(26): 4182–8.
  52. Karuturi M., Hosing C., Fanale M. et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol. Blood Marrow Transplant. 2013; 19(6): 991–4.
  53. Bierman P., Naushad H., Loberiza F. et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) for lymphocyte predominant Hodgkin’s disease [abstract]. Blood. 2006; 108(11): Abstract 3061.
  54. Jackson C., Sirohi B., Cunningham D. et al. Lymphocyte-predominant Hodgkin lymphoma — clinical features and treatment outcomes from a 30-year experience. Ann. Oncol. 2010; 21(10): 2061–8.
  55. Eichenauer D.A., Fuchs M., Pluetschow A. et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011; 118(16): 4363–5.
  56. Park H.C., Jung S.H., Ahn J.S. et al. Rituximab plus ifosfamide, carboplatin and etoposide for T-cell/histiocyte-rich B-cell lymphoma arising in nodular lymphocyte-predominant Hodgkin’s lymphoma. Case Rep. Oncol. 2012; 5(2): 413–9.
  57. Ekstrand B.C., Lucas J.B., Horwitz S.M. et al. Rituximab in lymphocytepredominant Hodgkin disease: results of a phase 2 trial. Blood. 2003; 101(11): 4285–9.
  58. Schulz H., Rehwald U., Morschhauser F. et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008; 111(1): 109–11.
  59. Advani R.H., Buggy J.J., Sharman J.P. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J. Clin. Oncol. 2013; 31(1): 88–94.
  60. Advani R.H., Horning S.J., Hope RT. et al. Mature results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. J. Clin. Oncol. 2014; 32(9): 912–8.